Conservative management of a transdiaphragmatic fistula

I Gee, G M Wood

Abstract
Case reports of transdiaphragmatic fistulas connecting subphrenic collections and empyemas are uncommon. We report the rare complication of a fistulous connection between a subphrenic collection and the bronchial tree.

(Thorax 2000;55:438–439)

Keywords: transdiaphragmatic fistula; subphrenic abscess

Case report
An 82 year old man was admitted following an episode of coffee ground vomiting. He had experienced a dull ache in the epigastrium for one week and had a history of a duodenal ulcer 20 years previously. He looked pale with a regular pulse of 100 bpm and there was mild epigastric tenderness. His haemoglobin was 123 g/l.

Gastroscopic examination showed a dilated stomach with fluid residue and the pylorus was narrowed to a pinhole; the duodenum could not be seen. He was started on lansoprazole and over the following week his condition stabilised. His haemoglobin fell to 107 g/l but he did not pass melaena.

He then became unwell with a pyrexia of 38°C, was tachypnoeic, and developed coarse crackles in the right lower chest. A diagnosis of right basal pneumonia was made and he was treated with intravenous cefuroxime and clarithromycin. Blood cultures were taken which yielded heavy growths of methicillin resistant Staphylococcus aureus, thought to be a skin contaminant. Both sputum and bronchial washings yielded Staphylococcus spp.

His haemoglobin was 125 g/l, white cell count 109/l, and chest radiography showed homogenous opacity at the right base which was thought not to be entirely caused by the effusion.

He was started on co-amoxiclav and erythromycin but attempted intercostal aspiration of the pleural fluid was unsuccessful. A barium enema was performed and indicated early diverticular disease in the sigmoid colon and a tiny outpouching at the hepatic flexure with some possible tethering. The significance of this was uncertain but possible causes included the previous perforation of a colonic diverticulum.

Bronchoscopic examination of the right bronchial tree indicated some inflammatory changes in the right lower lobe. A foul faeculent smell was noted and the possibility of a transdiaphragmatic fistula was raised. An abdominal ultrasound examination demonstrated a 12 cm collection of fluid lateral to the liver, suggestive of a subphrenic abscess. Later that day a pigtail drainage catheter was inserted into the subphrenic collection and thick pus was drained.

Two days later a tubogram was performed to assess the size of the abscess cavity. A small subphrenic cavity was demonstrated before the patient started to cough up contrast medium. Radiography showed a fistula between the subphrenic cavity and the bronchial tree (fig 1).

Pus from the subphrenic abscess cavity yielded heavy growths of methicillin resistant Staphylococcus aureus and Enterococcus spp. Both sputum and bronchial washings yielded methicillin resistant S. aureus. The patient was treated with teicoplanin and the cavity drained externally. Subsequent tubograms over the following week showed that the fistula had closed and the abscess cavity became smaller.

Following drainage of the abscess the patient made a good recovery and his chest symptoms resolved. He was discharged home and was well when seen two months later.
Mechanism of osteoporosis in patients with cystic fibrosis

In a recent issue of Thorax Haworth and coworkers reported that low bone mineral density—that is, osteoporosis—commonly occurred in patients with cystic fibrosis. This elderly patient presented with chest symptoms and was found to have a subphrenic abscess by ultrasound scanning. These pathologies were not initially thought to be connected but opinion changed when the patient expectorated contrast medium which had been injected into the subphrenic abscess cavity. It was decided that the best treatment option was to continue percutaneous drainage of the abscess and to administer antibiotics. This led to a satisfactory outcome and the transdia- phragmatic fistula closed spontaneously even when the abscess cavity had drained for a few days. It is not clear why this patient developed a subphrenic abscess but it must have arisen following his first hospital admission because the original ultrasound examination was normal. The possibilities include perforation of a colonic diverticulum or a duodenal ulcer. The barium enema findings suggested that a small diverticular perforation had occurred which had sealed spontaneously and the microbiota had suggested a faecal origin to the abscess, so this seems the most likely explanation. Alternatively, the dyspeptic symptoms, the fall in haemo-globin, and the previous history of a peptic ulcer raises the possibility of a silent perforation of a duodenal ulcer with subsequent healing. Pyloric stenosis prevented this possibility being confirmed at gastroscopy. The erosion of an empyema through the diaphragm following an earlier chest infection seems unlikely.


Letters to the editor

SHINJI TERAMOTO
Department of Internal Medicine, Saiseikai Hospital, International University of Health and Welfare, 3-35-14-305 Bubuhito-cho, Toshima-ku, Tokyo, Japan 171-0014 email: shinji-ter@umin.ac.jp

Discussion

Case reports of transdiaphragmatic fistulas connecting subphrenic collections and empyemae are uncommon.1 2 This elderly patient presented with chest symptoms and was found to have a subphrenic abscess by ultrasound scanning. These pathologies were not initially thought to be connected but opinion changed when the patient expectorated contrast medium which had been injected into the subphrenic abscess cavity. It was decided that the best treatment option was to continue percutaneous drainage of the abscess and to administer antibiotics. This led to a satisfactory outcome and the transdia- phragmatic fistula closed spontaneously even when the abscess cavity had drained for a few days. It is not clear why this patient developed a subphrenic abscess but it must have arisen following his first hospital admission because the original ultrasound examination was normal. The possibilities include perforation of a colonic diverticulum or a duodenal ulcer. The barium enema findings suggested that a small diverticular perforation had occurred which had sealed spontaneously and the microbiota may have suggested a faecal origin to the abscess, so this seems the most likely explanation. Alternatively, the dyspeptic symptoms, the fall in haemoglobin, and the previous history of a peptic ulcer raises the possibility of a silent perforation of a duodenal ulcer with subsequent healing. Pyloric stenosis prevented this possibility being confirmed at gastroscopy. The erosion of an empyema through the diaphragm following an earlier chest infection seems unlikely.


3 Teramoto S, Matsuse T, Ouchi Y. Increased cytokines may be responsible for the pamidronate-induced bone pain in adult patients with cystic fibrosis. Lancet 1999;352:1753–4.

AUTHORS’ REPLY We thank Shinji Teramoto for his con- tinued interest in our work and note his current (and previous) comments about the possible role of proin- flammatory cytokines in the development of low bone mineral density in patients with cystic fibrosis.1 As stated in our discussion, serum factor II, interleukin 1, and interleukin 6 may influence osteoclast activity in patients with cystic fibrosis. In fact, the significant negative relationship between the mean bone mineral density Z score and the C reactive protein concentration in our study provides the first evidence of an association between chronic pulmonary infection/inflammation and low bone mineral density in the cystic fibrosis population. Cystic fibrosis patients with low bone mineral density do not necessarily have osteo- porosis. It is important to emphasise that the precise histomorphometric characteristics of cystic fibrosis bone have not been comprehensively described. In our study 38% of patients were vitamin D insufficient, which may predispose them to osteoporosis, but 7% of patients had 25-hydroxyvitamin D levels associated with osteomalacia.3 Thus, some patients could have both osteoporosis and osteomalacia. Furthermore, a recent report suggested that the bone disease of cystic fibrosis was complex and possibly unique.1 We have previously reported that bone pain is common in patients with cystic fibrosis after intravenous pamidronate infusion and that it might be prevented by the concomitant use of oral corticosteroids.4 It is important to clarify that this was a retrospective observation and has not been evaluated prospectively.

CHARLES HAWORTH
KEVIN WEBB
Manchester Adult Cystic Fibrosis Unit, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Manchester M23 9LX, UK

1 Teramoto S, Matsuse T, Ouchi Y. Increased pro-duction of TNF-α may play a role in osteoporosis in cystic fibrosis. Chest 1997;112:574.
Spirometry in primary care

Contrary to Dr Pearson’s assertion in his reply in the May 1999 issue of Thorax, spirometry and the home recording of peak flow in COPD (FEV1) are not yet here to stay in general practice. The evidence is just not good enough. We were concerned by the inaccuracies in his letter which simply serve to underline our unease with the chronic obstructive pulmonary disease (COPD) guidelines. We will come to these later but, firstly, how is FEV1 related to peak expiratory flow rate (PEFR) in patients with COPD? Is FEV1 really essential in the day to day management of COPD? Spirometry is central to the accurate diagnosis of COPD in many patients. The ratio of FEV1 to FVC is indispensable in differentiating restrictive from obstructive patterns of respiratory function. But, unlike FEV1, it has its own offer additional information about COPD which is not available with PEFR. FEV1, represents the volume of air expired during the first second of forced expiration whereas PEFR represents the maximal flow rate (usually attained in the first 100 milliseconds). Both are derived from the flow rate, but the nub of the argument is what happens after the peak is reached. Pearson suggests that one needs to go, not to epidemiology, but to physiology to understand this issue. He suggests that, in patients with COPD, flow rate falls dramatically after peak expiratory flow is reached which is certainly the case in the day to day management of COPD. This supports the close correlation observed in practice.

The basis for using spirometry rather than peak flow in the day to day management of COPD demands a more rigorous approach than is evident from either the COPD guidelines or Dr Pearson’s letter. The issue is far from resolved and current evidence is an inadequate basis on which to recommend the widespread practice of spirometric testing in primary care.

PATRICK T WHITE
DESMUT NOLAN
Department of General Practice
and Primary Care, Northumberland and Tyne and Wear Local Health Authorities, Newcastle upon Tyne


department@nnpic.nct.nhs.uk

DERMOT NOLAN
Department of General Practice
and Primary Care, Westyn Education Centre, London SES 9PJ, UK


AUTHOR’S REPLY

Drs White and Nolan agree that spirometry is essential for the diagnosis of COPD and, on this basis alone, I would stand by the recommendations and guidelines that GP’s need to have access to spirometry. The COPD guidelines set out three options: GP owned spirometers, a mobile service visiting practices intermittently, or open access services at hospital. Whichever option is preferred locally, the spirometric tests must be performed by trained staff to ensure adequate quality control. Single measures of peak expiratory flow (PEF) are not adequate. It is colleagues in primary care who have encouraged those involved in guidelines to believe that PEF would probably provide a useful tool in their practice. The BTS COPD consortium has been promoting spirometry for the diagnosis of COPD since, without a correct diagnosis, the chance of accurate treatment is low. How the service is provided is a matter of local choice, not for national dictum.

With regard to the day to day management of COPD after the diagnosis has been objectively made, Drs White and Nolan are concerned that spirometry is not a necessary. In fact, no-one is recommending frequent regular spirometric testing. Serial measurements of FEV1, can and do provide evidence of progression over the years, but cannot detect changes over periods of less than a few years with any degree of confidence because the rate of decline is small relative to the coefficient of variability for the measurement. Since PEF is even more variable, it is of even less value as a monitoring tool and, in fact, the evidence suggests that PEF may be even less valid than PEFR.1–3

How the service is provided is a matter of local choice, not for national dictum. I am heartened by data presented at the recent British Thoracic Society meeting in which spirometry was used in primary care as a screening tool in a research project. It offered spirometry to all adults over 45 attending the surgery (smokers and non-smokers) and detected 6% of those studied as having undiagnosed symptomatic COPD, a high yield of treatable disease from

166

Downloaded from http://thorax.bmj.com/ on May 30, 2017 - Published by group.bmj.com
an inexpensive programme. Other primary care studies are in progress. I remain of the view that, in time, all GPs will have easy access to spirometry and be able to interpret the results as efficiently as they presently measure and manage blood pressure or blood sugar.

M G PEARSON
Aintree Chest Centre, Fazakerley Hospital, Liverpool L9 1AL, UK


Asthma guidelines

One problem with large studies that focus on a limited number of patient relevant outcomes endorsed by Tattersfield and Harrison is that the mean response to a given drug may hide a wide variability in individual response. This is particularly likely to occur in patients with symptomatic asthma despite treatment with low/moderate doses of inhaled corticosteroids. Studies have shown marked heterogeneity of airway inflammation and disordered airway function in these patients and there are wide differences in the effects of the candidate drugs on these measures. Smaller crossover studies comparing the effects of different treatments in patients who have been extensively characterised are needed in order to establish whether important heterogeneity of response occurs. Such studies may uncover easily identifiable patient characteristics that predict a response to an individual drug.

R H GREEN
I D PAVORD
Department of Respiratory Medicine & Thoracic Surgery, Glenfield General Hospital, Groby Road, Leicester LE3 9QF, UK


AUTHORS’ REPLY Patients with asthma clearly vary in their response to drugs and it is possible that smaller detailed studies will allow the identification of patients more likely to respond to a particular drug. For such a test to be useful in practice, however, it would need to be easily accessible, reliable, and have a very high predictive value. History suggests that it is often more practicable for the patient to undergo a trial of a drug, rather than to undergo an indirect assessment which is unlikely to be 100% predictive of the response and hence may result in some patients not receiving a drug from which they would benefit.

A E TATTERSFIELD
T HARRISON
Division of Respiratory Medicine, University of Nottingham, City Hospital, Nottingham NG5 1PB, UK

Respiratory questionnaires in COPD

The use of health status as an outcome measure in chronic obstructive pulmonary disease (COPD) is becoming more popular. We therefore welcome the publication of information which improves the choice of appropriate questionnaire. The recent paper by Rutten-van Molken and colleagues could have made an important contribution to this area. However, we are seriously concerned about the validity of their comparison between the St George’s Questionnaire (SGRQ) and the Chronic Respiratory Questionnaire (CRQ).

The clinical usefulness of the CRQ is limited because it is interviewer led while the SGRQ is self-administered. The development of a validated self-administered version of the CRQ would be a major advantage for clinical trials and clinical practice. The authors give the impression that a validated self-administered version of the CRQ already exists and have used this in their study. However, such a version is not described in the original reference as claimed and has never been disseminated by publication.

We have recently been working with the original authors of the CRQ to develop and validate a self-reported CRQ and the results have so far only been published in abstract form. We therefore believe that the results described in the paper are devoured by the misleading implication that a self-report version of the CRQ has been correctly developed.

J WILLIAMS
S J SINGH
M D L MORGAN
Department of Respiratory Medicine, Glenfield General Hospital, Leicester LE3 9QF, UK

1 Rutten-van Molken M, Roos B, Van Noord JA. An empirical comparison of the St George’s Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical setting. Thorax 1999;54:995–1003.
3 Williams J, Singh S, Morgan MDL. A comparison between a self-reported Chronic Respiratory Questionnaire (CRQ SR) and the conventional interviewer led CRQ. Eur Respir J 1999;14(Suppl 30):116s.

Athletes and fenoterol

In a review of doping in athletes by Dr Dekhuijzen published recently in Thorax the substance fenoterol was included in table 2 which listed respiratory drugs permitted by the International Olympic Committee (IOC). However, according to the IOC fenoterol is prohibited. Only salbutamol, salmeterol, and terbutaline are permitted by inhaler to prevent or treat asthma or exercise induced asthma. A written notification is necessary.

To prevent positive doping cases caused by misinformation of athletes and their advisors which might cause questions of retest, it is necessary to print a correction.

M K HENZE
Deutsche Sporthochschule Köln, 50933 Köln, Germany


AUTHORS’ REPLY We thank Dr Henze for this correction. As in the case of formoterol, there is no scientific reasoning given by the IOC for fenoterol not to be permitted by inhalation, in contrast to salbutamol, terbutaline, and salmeterol. There are no specific pharmacological or pharmacodynamic characteristics of inhaled fenoterol or formoterol that would predict a relevant stimulating effect on the respiratory system. For clarity we reproduce here the correct list of permitted respiratory drugs.

**Asthma education**

Drs Neville and Higgins ask what more can be done to provide better asthma care. They mention the importance of education but, before we can teach patients, we must resolve our own confusion about treatment.

Evidence shows that it is important to stamp out the inflammatory process in the bronchial tree as soon as the diagnosis of asthma has been confirmed, yet patients are still prescribed a short acting β agonist bronchodilator as the drug of first choice. This is given partly as a diagnostic test and achieves symptom control with full reversibility and optimal lung function.

Dr Strube points out that with an inadequate dose of inhaled steroids, inflammation and bronchial hyperreactivity persist, and that the frequency of symptoms is not reduced, and optimal lung function is never achieved.

Another approach to management is to start all new asthmatic patients at step 2 of the BTS guidelines, using a large dose of steroids as soon as the diagnosis has been confirmed by PFR monitoring. There is then no agonising over whether or not to give steroids or what dose to use.

Thus, these patients learn that steroids are the correct treatment for their asthma. The large initial dose recommended stamps out the active inflammatory process and achieves symptom control with full reversibility and optimal lung function.

The latter approach is being increasingly adopted by asthma nurses and many thinking doctors but some will misinterpret the BTS guidelines and allow their patients to become addicted to β agonists.

We would point out that we are not attempting to prove Dr Strube wrong. We cannot do so, any more than he can prove that his letter is right. What is important is that guidelines are based on the best evidence available and, at the moment, we lack the information needed to resolve the issue.

**AUTHORS’ REPLY**

Dr Strube’s letter addresses an interesting and important question. It is an issue which deserves proper debate, and most Thorax readers will recognise that that is exactly what it has had in the recent pages of the BMJ. Because of this, and because the question has been suggested, only the most tenuous link to our article, we will reply only briefly.

Dr Strube makes the case for using inhaled steroids in all asthma with conviction, but his supporting arguments are a mixture of circumstantial evidence and his own perception of the psychology of asthmatic patients. There is simply no direct trial evidence to show benefit from blanket administration of inhaled steroids to all new asthmatics. Good evidence certainly exists in asthma of moderate severity or greater, but the situation is less straightforward in patients with mild asthma where the case is unproven. Since there are valid reasons, aired elsewhere, for not using inhaled steroids unless necessary, it is fair to ask for some proof before committing patients to long term therapy in this way.

In addition to the lack of evidence, the approach advocated by Dr Strube assumes a certainty of diagnosis which many would feel to be unrealistic at the mild end of the asthma spectrum. It is easy to write that inhaled steroids should be started “as soon as the diagnosis has been confirmed by PFR monitoring”, but this is an insensitive test which is least likely to confirm asthma in those in whom the need for inhaled steroids is most debatable.

A further part of his argument is that the current guidelines on introduction of inhaled steroids are misused. This, as Mike Rudolf pointed out in the published debate with Dr Strube, is irrelevant to the main question; if the guidelines are being misinterpreted, the remedy is to attack the misinterpretation, not the guideline.

We would point out that we are not attempting to prove Dr Strube wrong. We cannot do so, any more than he can prove that his letter is right. What is important is that guidelines are based on the best evidence available and, at the moment, we lack the information needed to resolve the issue. If and when the evidence is strong enough, the recommendation will appear as Dr Strube wishes. Until then, this is a question of faith rather than fact.

**NOTICE**

The International Pediatric Respiratory and Allergy Congress will be held on 1–4 April 2001 at the Prague Congress Center, Prague, Czech Republic. For further information contact the Congress Secretariat at the Congress Centre, Czech Medical Society, JEP Sokolská 31, CZ-120 26 Prague, Czech Republic. Telephone +4202 299898 or +4202 297271; fax +4202 294610 or +4202 24216836. Email: lonekova@cls.cz
Respiratory questionnaires in COPD

J WILLIAMS, S J SINGH and M D L MORGAN

Thorax 2000 55: 439
doi: 10.1136/thorax.55.5.439c

Updated information and services can be found at:
http://thorax.bmj.com/content/55/5/439.4

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/